HLB Pharmaceutical has set the first-stage offering price for its rights issue at 5,650 won per share. The company plans to announce the final offering price on September 8.

According to a recent regulatory filing, the shares to be issued total 10,762,332 registered common shares with a par value of 500 won. The calculation date for the first-stage offering price is July 31, 2026.

The company explained that the first-stage offering price was calculated by applying a 25% discount to the base price, which reflects the volume-weighted average stock prices over one-month and one-week periods starting from the third trading day prior to the new share allocation record date, as well as the most recent closing price.

The second-stage offering price will be calculated based on the third trading day prior to the existing shareholders' subscription date, and the final offering price will, in principle, be the lower of the first-stage and second-stage prices. However, if the price falls below the minimum offering price (60% of the volume-weighted average stock price over a certain period prior to the subscription date) stipulated by the Capital Markets Act and related regulations, that minimum threshold will take precedence.

The final offering price will be determined on the third trading day prior to the start of the existing shareholders' subscription period. It will subsequently be disclosed on the Financial Supervisory Service's Electronic Disclosure System (DART) and announced on the company's website. For reference, the related disclosure date is May 13, 2026.